Disopyramide

CHEMBL517 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
339.5 g/mol
LogP
3.2
Phase
4

A class IA antiarrhythmic drug used to treat and prevent ventricular arrhythmias and atrial fibrillation by blocking sodium channels in the heart, slowing conduction and reducing excitability. It also has significant anticholinergic effects, causing dry mouth, urinary retention, and constipation. It has negative inotropic effects and must be used cautiously in patients with heart failure.

Khối lượng phân tử

339,5000 g/mol

LogP

3,20

TPSA

59,20 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C

InChI

InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)

Molecular Formula

C21H29N3O

HBD / HBA

1 / 3

Liên kết có thể quay

8

Nguyên tử nặng

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A class IA antiarrhythmic drug used to treat and prevent ventricular arrhythmias and atrial fibrillation by blocking sodium channels in the heart, slowing conduction and reducing excitability. It also has significant anticholinergic effects, causing dry mouth, urinary retention, and constipation. It has negative inotropic effects and must be used cautiously in patients with heart failure.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Disopyramide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL517. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3114. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.